구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Keytruda (pembrolizumab) |
Overview Company | Merck |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Multiple solid tumors |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. |
Positioning Development positioning | Global IO standard |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. |
PK/PD Half-life | 22 h |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat |
Toxicology Major finding | Immune-related AEs |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-related AEs |
Clinical Selected reported efficacy | ORR 38% |
Clinical Reported ORR | 38% |
Clinical Result source | ClinicalTrials.gov NCT02444741 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02444741 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Keytruda (pembrolizumab) |
Overview Company | Merck |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Multiple solid tumors |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. |
Positioning Development positioning | Global IO standard |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. |
PK/PD Half-life | 22 h |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat |
Toxicology Major finding | Immune-related AEs |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-related AEs |
Clinical Selected reported efficacy | ORR 38% |
Clinical Reported ORR | 38% |
Clinical Result source | ClinicalTrials.gov NCT02444741 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02444741 |
추천 비교
추천 비교